Editorials

Can Methotrexate Prevent Knee Arthroplasties in Patients with Rheumatoid Arthritis? J.M. Kremer ..............2217

The Difficult Task of Assessing Psoriatic Arthritis A. Caull, M. Piga ..................2219

Articles


The Risk of TB in Patients with RA Treated with TNF-α Antagonist: A Metaanalysis of Both Randomized Controlled Trials and Registry/Cohort Studies J.W. Ai, S. Zhang, Q.L. Ruan, et al ........2229

Incidence and Predictors of Biological Antirheumatic Drug Discontinuation Attempts among Patients with RA in Remission: A CORRONA and NinJa Collaborative Cohort Study K. Yoshida, H. Radner, M.D. Mjaavatten, et al ....2238

RA: Trends in Antirheumatic Drug Use, C-reactive Protein Levels, and Surgical Burden A.B. Pedersen, A. Mor, F. Mehnert, R.W. Thomsen, S.P. Johnsen, M. Nørgaard .....................2247

Concomitant MTX Protects Against TKA in Patients with RA Treated with TNF Inhibitors S. Asai, N. Takahashi, K. Funahashi, et al ..........2255

Association of Body Mass Index Categories with Disease Activity and Radiographic Joint Damage in RA: A Systematic Review and Metaanalysis C. Vidal, T. Barnetche, J. Morel, B. Combe, C. Daïen .2261

Pregnancy Outcomes in Subjects Exposed to Certolizumab Pegol M.E. Clowse, D.C. Wolf, F. Förger, et al ........2270

Clinical and Radiographic Outcomes in Patients Diagnosed with Early RA in the First Years of the Biologic Treatment Era: A 10-year Prospective Observational Study G. Haugeberg, P. Bøyesen, K. Helgetveit, A. Proven ..................2279


A Multicenter Study of Invasive Fungal Infections in Patients with Childhood-onset SLE M.F. Silva, M.P. Ferriani, M.T. Terreri, et al ........2296

Risk Factors for Symptomatic Avascular Necrosis in Childhood-onset SLE Y. Yang, S. Kumar, L.S. Lim, E.D. Silverman, D.M. Levy ......................2304


Applying the ACR/EULAR Systemic Sclerosis Classification Criteria to the Spanish Scleroderma Registry Cohort L. Sáez-Comet, C.P. Simeon-Aznar, M. Pérez-Conesa, et al, and the RESCLE Investigators ....2327

Patient’s Global Assessment as an Outcome Measure for PsA in Clinical Practice: A Surrogate for Measuring Low Disease Activity? E. Lubrano, F.M. Perrotta, W.J. Parsons, A. Marchesonhi ..................2332


Fatigue in Ankylosing Spondylitis and Nonradiographic AxSpA: Analysis from a Longitudinal Observation Cohort M. Bedaiwi, I. Sari, A. Thavaneswaran, R. Ayeaest, N. Haroon, R.D. Inman ......................2354

Discriminant Capacity of Clinical Efficacy and Nonsteroidal Antiinflammatory Drug-sparing Endpoints, Alone or in Combination, in AxSpA M. Dougados, E. Wood, L. Gossec, A. Dubanchet, I. Logeart, D. van der Heijde .....................2361

Accelerometer Quantification of Physical Activity and Activity Patterns in Patients with Ankylosing Spondylitis and Population Controls S. van Genderen, A. Boonen, D. van der Heijde, et al ..............2369

